tetano
Editor, Senior Moderator
Leuk Lymphoma
. 2021 Jul 22;1-11.
doi: 10.1080/10428194.2021.1948031. Online ahead of print.
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Tomás Palanques-Pastor[SUP] 1 [/SUP], Juan Eduardo Megías-Vericat[SUP] 1 [/SUP], Pilar Martínez[SUP] 2 [/SUP], José Luis López Lorenzo[SUP] 3 [/SUP], Javier Cornago Navascués[SUP] 3 [/SUP], Gabriela Rodriguez Macias[SUP] 4 [/SUP], Isabel Cano[SUP] 5 [/SUP], Montserrat Arnan Sangerman[SUP] 6 [/SUP], María Belén Vidriales Vicente[SUP] 7 [/SUP], Jesús Lorenzo Algarra Algarra[SUP] 8 [/SUP], María Ángeles Foncillas[SUP] 9 [/SUP], Pilar Herrera[SUP] 10 [/SUP], Carmen Botella Prieto[SUP] 11 [/SUP], Susana Vives[SUP] 12 [/SUP], Ángela Figuera Álvarez[SUP] 13 [/SUP], Laida Cuevas Palomares[SUP] 14 [/SUP], Marta Sobas[SUP] 15 [/SUP], Alejandro Contento Gonzalo[SUP] 16 [/SUP], Rebeca Cuello García[SUP] 17 [/SUP], María Elena Amutio Diez[SUP] 18 [/SUP], Dunia De Miguel Llorente[SUP] 19 [/SUP], Begoña Navas Elorza[SUP] 20 [/SUP], Juan Miguel Bergua Burgues[SUP] 21 [/SUP], Teresa Bernal Del Castillo[SUP] 22 [/SUP], María Carmen Mateos Rodríguez[SUP] 23 [/SUP], Erik de Cabo López[SUP] 24 [/SUP], Ana Carolina Franco Villegas[SUP] 25 [/SUP], Raimundo García Boyero[SUP] 26 [/SUP], Cristian Escolano Escobar[SUP] 27 [/SUP], Cristina Seri Merino[SUP] 28 [/SUP], Carlos Cervero[SUP] 29 [/SUP], Alicia Roldán Pérez[SUP] 30 [/SUP], Lourdes Hermosín Ramos[SUP] 31 [/SUP], Marta Cervera Calvo[SUP] 32 [/SUP], María Telesa Olave[SUP] 33 [/SUP], Paola Villafuerte Gutiérrez[SUP] 34 [/SUP], Almudena de Laiglesiai[SUP] 35 [/SUP], Josefina Serrano[SUP] 36 [/SUP], María Josefa Najera Irazu[SUP] 37 [/SUP], José Luis Piñana[SUP] 5 [/SUP], Miguel Ángel Sanz[SUP] 5 [/SUP], Joaquín Martínez-López[SUP] 2 [/SUP], Pau Montesinos[SUP] 5 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.
Keywords: COVID-19; SARS-CoV-2; acute myeloid leukemia; hematological malignancies.
. 2021 Jul 22;1-11.
doi: 10.1080/10428194.2021.1948031. Online ahead of print.
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Tomás Palanques-Pastor[SUP] 1 [/SUP], Juan Eduardo Megías-Vericat[SUP] 1 [/SUP], Pilar Martínez[SUP] 2 [/SUP], José Luis López Lorenzo[SUP] 3 [/SUP], Javier Cornago Navascués[SUP] 3 [/SUP], Gabriela Rodriguez Macias[SUP] 4 [/SUP], Isabel Cano[SUP] 5 [/SUP], Montserrat Arnan Sangerman[SUP] 6 [/SUP], María Belén Vidriales Vicente[SUP] 7 [/SUP], Jesús Lorenzo Algarra Algarra[SUP] 8 [/SUP], María Ángeles Foncillas[SUP] 9 [/SUP], Pilar Herrera[SUP] 10 [/SUP], Carmen Botella Prieto[SUP] 11 [/SUP], Susana Vives[SUP] 12 [/SUP], Ángela Figuera Álvarez[SUP] 13 [/SUP], Laida Cuevas Palomares[SUP] 14 [/SUP], Marta Sobas[SUP] 15 [/SUP], Alejandro Contento Gonzalo[SUP] 16 [/SUP], Rebeca Cuello García[SUP] 17 [/SUP], María Elena Amutio Diez[SUP] 18 [/SUP], Dunia De Miguel Llorente[SUP] 19 [/SUP], Begoña Navas Elorza[SUP] 20 [/SUP], Juan Miguel Bergua Burgues[SUP] 21 [/SUP], Teresa Bernal Del Castillo[SUP] 22 [/SUP], María Carmen Mateos Rodríguez[SUP] 23 [/SUP], Erik de Cabo López[SUP] 24 [/SUP], Ana Carolina Franco Villegas[SUP] 25 [/SUP], Raimundo García Boyero[SUP] 26 [/SUP], Cristian Escolano Escobar[SUP] 27 [/SUP], Cristina Seri Merino[SUP] 28 [/SUP], Carlos Cervero[SUP] 29 [/SUP], Alicia Roldán Pérez[SUP] 30 [/SUP], Lourdes Hermosín Ramos[SUP] 31 [/SUP], Marta Cervera Calvo[SUP] 32 [/SUP], María Telesa Olave[SUP] 33 [/SUP], Paola Villafuerte Gutiérrez[SUP] 34 [/SUP], Almudena de Laiglesiai[SUP] 35 [/SUP], Josefina Serrano[SUP] 36 [/SUP], María Josefa Najera Irazu[SUP] 37 [/SUP], José Luis Piñana[SUP] 5 [/SUP], Miguel Ángel Sanz[SUP] 5 [/SUP], Joaquín Martínez-López[SUP] 2 [/SUP], Pau Montesinos[SUP] 5 [/SUP]
Affiliations
- PMID: 34292118
- DOI: 10.1080/10428194.2021.1948031
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.
Keywords: COVID-19; SARS-CoV-2; acute myeloid leukemia; hematological malignancies.